GENB (Generate Biomedicines) Scaled Net Operating Assets: -1.50 (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Scaled Net Operating Assets?

Generate Biomedicines GENB +2.18% 6 Scaled Net Operating Assets is -1.50 as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Generate Biomedicines's operating assets for the quarter that ended in Dec. 2025 was $108.68 Mil. Generate Biomedicines's operating liabilities for the quarter that ended in Dec. 2025 was $884.85 Mil. Generate Biomedicines's Total Assets for the quarter that ended in Dec. 2024 was $518.26 Mil. Therefore, Generate Biomedicines's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was -1.50.

Generate Biomedicines Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Scaled Net Operating Assets Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Scaled Net Operating Assets
-1.45 -1.50

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Scaled Net Operating Assets -1.45 -1.50

GENB vs PVLA, SLBT, NKTR: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Generate Biomedicines's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's Scaled Net Operating Assets falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Generate Biomedicines's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(108.684-884.853)/518.259
=-1.50

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=330.182 - 221.498
=108.684

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=953.379 - 53.518 - 15.008
=884.853

Generate Biomedicines's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Dec. 2024 )
=(108.684-884.853)/518.259
=-1.50

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=330.182 - 221.498
=108.684

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=953.379 - 53.518 - 15.008
=884.853

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.50 mean?
Generate Biomedicines (GENB) has a Scaled Net Operating Assets of -1.50 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Scaled Net Operating Assets too high?
Generate Biomedicines' current Scaled Net Operating Assets is -1.50. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Scaled Net Operating Assets compare to PVLA and SLBT?
Generate Biomedicines' Scaled Net Operating Assets of -1.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Scaled Net Operating Assets is -1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Scaled Net Operating Assets of -1.50. The current Scaled Net Operating Assets is -1.50. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Scaled Net Operating Assets is -1.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price